Submit Search
Upload
2010StanfordE25 Michele dragoescu e25 project
•
Download as PPT, PDF
•
0 likes
•
472 views
M
mdragoescu
Follow
Technology
Slideshow view
Report
Share
Slideshow view
Report
Share
1 of 26
Download now
Recommended
23andMe President and Co-Founder Anne Wojcicki Addresses FDA/CDRH Public Meeting on Oversight of Laboratory Developed Tests (LDTs), July, 20, 2010
Anne Wojcicki of 23andMe at FDA Public Meeting on LDTs, July 20, 2010
Anne Wojcicki of 23andMe at FDA Public Meeting on LDTs, July 20, 2010
The Spittoon
View the webinar at: http://www.knome.com/webinar-big-data-genomic-medicine. This presentation covers an overview of genomic medicine, requirements and challenges of next-generation sequencing, bottlenecks to broader healthcare adoption, and why “we want to sequence everyone.”
Big Data and Genomic Medicine by Corey Nislow
Big Data and Genomic Medicine by Corey Nislow
Knome_Inc
Our last webcast introduced the newest features of VarSeq that will be included in our upcoming release. After a serious developmental effort, we are excited to announce one of these being the integration of ACMG Guidelines for CNVs! VarSeq is not only the tertiary environment to filter through your imported SNVs and indels from any VCF file, but also includes robust and proven capabilities of CNV detection and clinical variant interpretation. With our upcoming release, users will be able to leverage an automated CNV ACMG classification filter that is paired with the CNV evaluation in the VSClinical interpretation hub. This webcast will expose attendees to literature reinforcing the quality of our CNV caller, as well as showing examples of CNV analysis to demonstrate how this tool can streamline the analysis process. In this webcast, we will cover: Describing the new CNV guidelines and how Golden Helix tackles their complexity Assessing CNV impact on Gene and Gene Dosage Cited literature referencing the accuracy of VarSeq’s CNV calling Product demonstrations of VSClinical’s CNV interpretation/classification and final report functionalities Manually traversing the guidelines and classification process is fundamentally complex with multiple criteria considerations, collecting any necessary caveats, and bulk literature review just to name a few. It is our goal to simplify and streamline this process without losing user-control of final results or overlooking any crucial criteria components necessary for final classification. We hope you will join us to see how this is accomplished as we explore the ACMG CNV Guidelines within VSClinical from the user’s perspective!
A User’s Perspective: ACMG Guidelines for CNVs in VSClinical
A User’s Perspective: ACMG Guidelines for CNVs in VSClinical
Golden Helix
As CNV detection has become widely adopted as a component of NGS testing, the demand has grown for an interpreting framework specific to CNVs in the context of rare and inherited disorders. Earlier this year, a ClinGen working group in collaboration with ACMG, published new guidelines for the interpreting and reporting of CNVs detected by NGS. We at Golden Helix have been hard at work expanding VSClinical to incorporate these new scoring and evaluation criteria for the interpretation and clinical reporting of CNVs alongside small variants in our popular guided workflow for following the ACMG guidelines. Please join us in this webinar as we preview the upcoming release of VarSeq with this major development. We will cover the following: - The new CNV guidelines, the specialized criteria for gains and losses, and how VSClinical simplifies the scoring and interpretation process - How VS-CNV and VSClinical provides a complete solution for clinical detection and interpretation of CNVs for NGS gene panels and exomes - The number of CNV specific data sources curated and integrated into the automatic recommendation system - VSClinical’s integrated Word-based template system for designing custom clinical reports that include quality summary information, coverage at exon and gene level, interpreted variants and CNVs, and patient-level results We are excited to release this major update to VSClinical, incorporating many small feature enhancements and user requests alongside with the integration of the CNV guidelines. Please join us in this webinar to see how CNVs can be an integrated part of the analysis workflow for your clinical NGS tests.
VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...
VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...
Golden Helix
http://www.fao.org/about/meetings/wgs-on-food-safety-management/en/ Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infection Control in an Institutional Setting. Presentation from the Technical Meeting on the impact of Whole Genome Sequencing (WGS) on food safety management and GMI-9, 23-25 May 2016, Rome, Italy.
Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infectio...
Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infectio...
ExternalEvents
Open-Source Bioinformatics for Data Scientists with Amanda Schierz
Open-Source Bioinformatics for Data Scientists with Amanda Schierz
Open-Source Bioinformatics for Data Scientists with Amanda Schierz
Jessica Willis
Research2.0
23and me
23and me
tobyo_init
Nano-Medicine Global Market
Nano-Medicine Global MarketNano medicine global market
Nano-Medicine Global MarketNano medicine global market
pharmaindexing
Recommended
23andMe President and Co-Founder Anne Wojcicki Addresses FDA/CDRH Public Meeting on Oversight of Laboratory Developed Tests (LDTs), July, 20, 2010
Anne Wojcicki of 23andMe at FDA Public Meeting on LDTs, July 20, 2010
Anne Wojcicki of 23andMe at FDA Public Meeting on LDTs, July 20, 2010
The Spittoon
View the webinar at: http://www.knome.com/webinar-big-data-genomic-medicine. This presentation covers an overview of genomic medicine, requirements and challenges of next-generation sequencing, bottlenecks to broader healthcare adoption, and why “we want to sequence everyone.”
Big Data and Genomic Medicine by Corey Nislow
Big Data and Genomic Medicine by Corey Nislow
Knome_Inc
Our last webcast introduced the newest features of VarSeq that will be included in our upcoming release. After a serious developmental effort, we are excited to announce one of these being the integration of ACMG Guidelines for CNVs! VarSeq is not only the tertiary environment to filter through your imported SNVs and indels from any VCF file, but also includes robust and proven capabilities of CNV detection and clinical variant interpretation. With our upcoming release, users will be able to leverage an automated CNV ACMG classification filter that is paired with the CNV evaluation in the VSClinical interpretation hub. This webcast will expose attendees to literature reinforcing the quality of our CNV caller, as well as showing examples of CNV analysis to demonstrate how this tool can streamline the analysis process. In this webcast, we will cover: Describing the new CNV guidelines and how Golden Helix tackles their complexity Assessing CNV impact on Gene and Gene Dosage Cited literature referencing the accuracy of VarSeq’s CNV calling Product demonstrations of VSClinical’s CNV interpretation/classification and final report functionalities Manually traversing the guidelines and classification process is fundamentally complex with multiple criteria considerations, collecting any necessary caveats, and bulk literature review just to name a few. It is our goal to simplify and streamline this process without losing user-control of final results or overlooking any crucial criteria components necessary for final classification. We hope you will join us to see how this is accomplished as we explore the ACMG CNV Guidelines within VSClinical from the user’s perspective!
A User’s Perspective: ACMG Guidelines for CNVs in VSClinical
A User’s Perspective: ACMG Guidelines for CNVs in VSClinical
Golden Helix
As CNV detection has become widely adopted as a component of NGS testing, the demand has grown for an interpreting framework specific to CNVs in the context of rare and inherited disorders. Earlier this year, a ClinGen working group in collaboration with ACMG, published new guidelines for the interpreting and reporting of CNVs detected by NGS. We at Golden Helix have been hard at work expanding VSClinical to incorporate these new scoring and evaluation criteria for the interpretation and clinical reporting of CNVs alongside small variants in our popular guided workflow for following the ACMG guidelines. Please join us in this webinar as we preview the upcoming release of VarSeq with this major development. We will cover the following: - The new CNV guidelines, the specialized criteria for gains and losses, and how VSClinical simplifies the scoring and interpretation process - How VS-CNV and VSClinical provides a complete solution for clinical detection and interpretation of CNVs for NGS gene panels and exomes - The number of CNV specific data sources curated and integrated into the automatic recommendation system - VSClinical’s integrated Word-based template system for designing custom clinical reports that include quality summary information, coverage at exon and gene level, interpreted variants and CNVs, and patient-level results We are excited to release this major update to VSClinical, incorporating many small feature enhancements and user requests alongside with the integration of the CNV guidelines. Please join us in this webinar to see how CNVs can be an integrated part of the analysis workflow for your clinical NGS tests.
VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...
VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...
Golden Helix
http://www.fao.org/about/meetings/wgs-on-food-safety-management/en/ Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infection Control in an Institutional Setting. Presentation from the Technical Meeting on the impact of Whole Genome Sequencing (WGS) on food safety management and GMI-9, 23-25 May 2016, Rome, Italy.
Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infectio...
Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infectio...
ExternalEvents
Open-Source Bioinformatics for Data Scientists with Amanda Schierz
Open-Source Bioinformatics for Data Scientists with Amanda Schierz
Open-Source Bioinformatics for Data Scientists with Amanda Schierz
Jessica Willis
Research2.0
23and me
23and me
tobyo_init
Nano-Medicine Global Market
Nano-Medicine Global MarketNano medicine global market
Nano-Medicine Global MarketNano medicine global market
pharmaindexing
DNA & Personalized Medicine
DNA & Personalized Medicine
e-Patient Connections
Gardner and Song_2015_Genetics in Medicine
Gardner and Song_2015_Genetics in Medicine
Amanda Natalizio
A description of the BRCA Share Consortium
The BRCA Share(TM) Consortium - Christophe Beroud
The BRCA Share(TM) Consortium - Christophe Beroud
Human Variome Project
Background: New technologies and increased competition have, and will continue to improve the cost-effectiveness of genetic testing, making genetic analysis more accessible to medical practices worldwide. However, challenges remain to establishing the validity of such tests. Moreover many patients harbor rare or novel variants and classification is likely to remain a bottleneck in broader deployment of genetic medicine.
Establishing validity, reproducibility, and utility of highly scalable geneti...
Establishing validity, reproducibility, and utility of highly scalable geneti...
Human Variome Project
Senior Director Meg Ehm, Human Genetics at GSK, at Genomics to Healthcare EU side event, 13 Sept 2019, THL, Helsinki
Meg Ehm: Fueling a Genetics-Driven Drug Discovery Organization
Meg Ehm: Fueling a Genetics-Driven Drug Discovery Organization
THL
Lecture on the role of NGS and Genomics in Healthcare
2016 ngs health_lecture
2016 ngs health_lecture
Dan Gaston
The rate of variant discovery continues to surpass the rate of clinicalgrade interpretation. This is a challenge for precision medicine, because fast, reliable access to variant interpretations is necessary to provide well-informed and timely interpretations of test results to patients. ClinVar is a public repository for interpretations of clinical significance and functional effects of variants in any gene and for any disease. Interpretations are submitted by many sources, including clinical testing laboratories, research laboratories, locus-specific databases, expert panels, practice guidelines, as well as OMIM® and GeneReviews™. Collecting variant interpretations in ClinVar depends on integrating data from these different sources, which has several benefits. First, data integration requires standardizing the data from each source. This improves the quality of the data in ClinVar as well as in each of the individual datasets. ClinVar staff validate HGVS expressions as a routine part of ClinVar submission processing. Submitters are encouraged to use standard terms in MedGen for diseases and phenotypes. Standard terms for clinical significance are used in ClinVar when available; for example, ClinVar uses the terms recommended by ACMG to classify variants for Mendelian diseases. Secondly, ClinVar aggregates all data for a variant defined by its genomic location. Therefore, HGVS descriptions on different transcripts or on different genomic sequences can be recognized as the same variant. Thirdly, integrating data from multiple submitters allows the evidence from all sources to be pooled together. This larger collection of evidence aids the re-evaluation of variant classifications, and is especially valuable for rare variants and novel gene-disease relationships. Fourthly, data integration means that variant interpretations from different sources can be viewed together and compared. Thus a ClinVar user has access to interpretations outside any internal system and knows when there is consensus in the interpretation or not. Submitting laboratories use reports of conflicting interpretations in ClinVar to prioritize variants that they should re-evaluate. ClinVar receives data from many data providers, and therefore provides clear attribution to each contributing group, including links to records in LSDBs. Each source may update their submission to ClinVar at any time. For example, a record may be updated when a variant is re-classified or when additional evidence is available to support the interpretation. Submitters may consider providing regular updates to ClinVar to prevent their interpretations from becoming out of date. Submissions to ClinVar describe variants that range in complexity from simple alleles with explicit sequence locations through copy number changes and cytogenetic rearrangements with fuzzy boundaries.
ClinVar: Aggregating Data to Improve Variant Interpretation - Melissa Landrum
ClinVar: Aggregating Data to Improve Variant Interpretation - Melissa Landrum
Human Variome Project
presentation at CC Advances 2014
0301 ostrer
0301 ostrer
tczucker
In this webcast, we feature several example workflows and helpful features in the VarSeq that can be used in the clinic. We discuss options for conducting a comprehensive gene panel analysis for cancer or hereditary diseases. Then we introduce an example of a single exome workflow that goes from an unfiltered VCF created by a secondary analysis pipeline to a report containing information about interesting variants. Finally, we walk through an example of a trio analysis showcasing a variety of different filter options as well as inheritance patterns. All these workflows will result in a customizable clinical report.
An Exploration of Clinical Workflows in VarSeq
An Exploration of Clinical Workflows in VarSeq
Golden Helix
Dr. Leroy Hood lectured to a group of Ohio State University College of Medicine students and faculty on May 13, 2010 in advance of an announcement of a partnership between the Ohio State University Medical Center and the Institute for Systems Biology. The partnership will be known as
Dr. Leroy Hood Lecuture on P4 Medicine
Dr. Leroy Hood Lecuture on P4 Medicine
The Ohio State University Wexner Medical Center
Pine Biotech held a workshop and discussion of the approaches that are being developed for the T-BioInfo platform. The approaches were presented by Julia Panov, a Ph.D. student from Haifa University and data scientist working at Pine Biotech. Her presentation covered some of the projects with preliminary results showing a promising method of integrating various omics data types and applying them to noisy datasets signal processing for target discovery and biomarkers. The workshop was held at the Flower Hall at Tulane University. This was the first presentation to over 40 people that gathered to discuss interesting applications of biomedical data analysis to healthcare and pharma. Dr. Yu-Ping Wang and Dr. Lars Gilbertson from the department of Biomedical Engineering also shared their perspective on this important topic. http://pine-biotech.com/workshop-roundtable-discussion-tulane-pine-biotech/
Tulane Workshop on Multi-omics integration
Tulane Workshop on Multi-omics integration
Elia Brodsky
Analysis and synthesis of a pulse survey conducted across >140 oncologists, pathologists, and lab directors regarding current adoption and trends associated with emerging oncology biomarkers and companion diagnostics (CDx), with an emphasis on next-generation sequencing (NGS)-based CDx.
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...
Andrew Aijian
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following: --Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals --Strategic client partnerships created by "Tech-Only" model --Dynamic, rapidly-growing and consolidating industry Industry-leading revenue & test volume growth --Strong productivity and operating leverage leading to accelerating cash flow and net income --Strong Management Team with large cap lab experience
Cancer Diagnostics Laboratory | NeoGenomics | April 2014 | Company Overview P...
Cancer Diagnostics Laboratory | NeoGenomics | April 2014 | Company Overview P...
NeoGenomics Laboratory | Cancer Diagnostics
Genomics, Bioinformatics, and Pathology
Genomics, Bioinformatics, and Pathology
Dan Gaston
AHIA 2011 Conference presentation by Prof Warwick Anderson, National health and Medical Research Centre
Genomics: The coming challenge to the health system
Genomics: The coming challenge to the health system
Private Healthcare Australia
http://www.fao.org/about/meetings/wgs-on-food-safety-management/en/ Web applications for rapid microbial taxonomy identification. Presentation from the Technical Meeting on the impact of Whole Genome Sequencing (WGS) on food safety management -23-25 May 2016, Rome, Italy.
Web applications for rapid microbial taxonomy identification
Web applications for rapid microbial taxonomy identification
ExternalEvents
VarSeq is a tertiary analysis platform that allows users to filter and annotate NGS sequencing data to identify clinically relevant variants. Following this workflow, VSClinical can then be used to automate both germline and somatic variant analysis in accordance with the ACMG and AMP guidelines by using a variety of functional prediction models and clinical and reviewer-based annotations. Once variant or biomarker interpretations are completed, they can be rendered in a customizable clinical report and stored in an internal assessment catalog as an internal variant database repository. Together, implementation of VSClinical will promote increased lab throughput as well as accuracy and compliance with the ACMG and AMP guidelines, which in turn can save time and money. To show the capabilities of our software, this webcast will provide a demonstration of how to use VarSeq and VSClinical for the evaluation of both germline and somatic variants in accordance with the ACMG and AMP Guidelines. In this webcast, we will cover: - Filter logics for germline and somatic variants and selecting them into the VSClinical interface - Capabilities of functional prediction and splice site algorithms for edge case variants - The functionality of changing the clinically relevant transcript on variant interpretation - Rendering a clinical report with germline and somatic variants with the inclusion of clinical trials
Next-Generation Sequencing Analysis in VSClinical
Next-Generation Sequencing Analysis in VSClinical
Golden Helix
Golden Helix has been in close communication with the publishers of the ACMG guidelines and the ClinGen group to receive expert advice on how to interpret CNVs called on NGS data. These guidelines provide a robust set of rules for interpreting intragenic deletions and duplications, which is summarized into an intricate decision tree that is broken down into 80 distinct criteria. This complexity is further compounded by many important caveats, exceptions, and considerations known to many in the CNV clinical workspace but are not mentioned in the published guidelines. Fortunately, Golden Helix has spent long hours reading the guidelines, watching the webinars, reading the supplementary material, and working with collaborators to develop a comprehensive workflow to guide you through your clinical interpretation of CNVs. Herein, we are excited to cover more details into this novel ACMG CNV guideline interpretation workflow and demonstrate how intuitive this feature can be for your clinical pipeline. Specifically, we will cover: The intricacies of the ACMG CNV Sample auto classifier Unique annotations and algorithms Adjustable metrics and parameters in the VSClinical ACMG interface Rendering clinical reports
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline Workflow
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline Workflow
Golden Helix
Darby Kammeraad, a Field Application Scientist at Golden Helix, gives some insight into the advantages of VarSeq's capability with annotations. The number of annotation topics to cover is seemingly limitless. In this webcast, he focuses on key elements that demonstrate the value of Golden Helix's curated annotations available in VarSeq and address some important considerations from our users. We also cover the types and effective utilization of annotations in VarSeq. Finally, he covers how users can create their own annotation sources from the Convert Wizard tool.
Annotation capabilities
Annotation capabilities
Golden Helix
Published in 2010, the MARS study outlines how consumers use the Web according to condition type and interests.
MARS Study Outlines Online Habits of Health Consumers
MARS Study Outlines Online Habits of Health Consumers
Path of the Blue Eye Project
Current status, cost, and applications of personal genome sequencing
DNA Testing: Living Longer Via Personal Genomics
DNA Testing: Living Longer Via Personal Genomics
Melanie Swan
헬스케어 빅데이터로 무엇을 할 수 있는가? 연구와 임상 적용 경험을 중심으로 (유전체, 전자의무기록, 건강보험청구자료, 영상, 센서/모바일)
헬스케어 빅데이터로 무엇을 할 수 있는가?
헬스케어 빅데이터로 무엇을 할 수 있는가?
Hyung Jin Choi
More Related Content
What's hot
DNA & Personalized Medicine
DNA & Personalized Medicine
e-Patient Connections
Gardner and Song_2015_Genetics in Medicine
Gardner and Song_2015_Genetics in Medicine
Amanda Natalizio
A description of the BRCA Share Consortium
The BRCA Share(TM) Consortium - Christophe Beroud
The BRCA Share(TM) Consortium - Christophe Beroud
Human Variome Project
Background: New technologies and increased competition have, and will continue to improve the cost-effectiveness of genetic testing, making genetic analysis more accessible to medical practices worldwide. However, challenges remain to establishing the validity of such tests. Moreover many patients harbor rare or novel variants and classification is likely to remain a bottleneck in broader deployment of genetic medicine.
Establishing validity, reproducibility, and utility of highly scalable geneti...
Establishing validity, reproducibility, and utility of highly scalable geneti...
Human Variome Project
Senior Director Meg Ehm, Human Genetics at GSK, at Genomics to Healthcare EU side event, 13 Sept 2019, THL, Helsinki
Meg Ehm: Fueling a Genetics-Driven Drug Discovery Organization
Meg Ehm: Fueling a Genetics-Driven Drug Discovery Organization
THL
Lecture on the role of NGS and Genomics in Healthcare
2016 ngs health_lecture
2016 ngs health_lecture
Dan Gaston
The rate of variant discovery continues to surpass the rate of clinicalgrade interpretation. This is a challenge for precision medicine, because fast, reliable access to variant interpretations is necessary to provide well-informed and timely interpretations of test results to patients. ClinVar is a public repository for interpretations of clinical significance and functional effects of variants in any gene and for any disease. Interpretations are submitted by many sources, including clinical testing laboratories, research laboratories, locus-specific databases, expert panels, practice guidelines, as well as OMIM® and GeneReviews™. Collecting variant interpretations in ClinVar depends on integrating data from these different sources, which has several benefits. First, data integration requires standardizing the data from each source. This improves the quality of the data in ClinVar as well as in each of the individual datasets. ClinVar staff validate HGVS expressions as a routine part of ClinVar submission processing. Submitters are encouraged to use standard terms in MedGen for diseases and phenotypes. Standard terms for clinical significance are used in ClinVar when available; for example, ClinVar uses the terms recommended by ACMG to classify variants for Mendelian diseases. Secondly, ClinVar aggregates all data for a variant defined by its genomic location. Therefore, HGVS descriptions on different transcripts or on different genomic sequences can be recognized as the same variant. Thirdly, integrating data from multiple submitters allows the evidence from all sources to be pooled together. This larger collection of evidence aids the re-evaluation of variant classifications, and is especially valuable for rare variants and novel gene-disease relationships. Fourthly, data integration means that variant interpretations from different sources can be viewed together and compared. Thus a ClinVar user has access to interpretations outside any internal system and knows when there is consensus in the interpretation or not. Submitting laboratories use reports of conflicting interpretations in ClinVar to prioritize variants that they should re-evaluate. ClinVar receives data from many data providers, and therefore provides clear attribution to each contributing group, including links to records in LSDBs. Each source may update their submission to ClinVar at any time. For example, a record may be updated when a variant is re-classified or when additional evidence is available to support the interpretation. Submitters may consider providing regular updates to ClinVar to prevent their interpretations from becoming out of date. Submissions to ClinVar describe variants that range in complexity from simple alleles with explicit sequence locations through copy number changes and cytogenetic rearrangements with fuzzy boundaries.
ClinVar: Aggregating Data to Improve Variant Interpretation - Melissa Landrum
ClinVar: Aggregating Data to Improve Variant Interpretation - Melissa Landrum
Human Variome Project
presentation at CC Advances 2014
0301 ostrer
0301 ostrer
tczucker
In this webcast, we feature several example workflows and helpful features in the VarSeq that can be used in the clinic. We discuss options for conducting a comprehensive gene panel analysis for cancer or hereditary diseases. Then we introduce an example of a single exome workflow that goes from an unfiltered VCF created by a secondary analysis pipeline to a report containing information about interesting variants. Finally, we walk through an example of a trio analysis showcasing a variety of different filter options as well as inheritance patterns. All these workflows will result in a customizable clinical report.
An Exploration of Clinical Workflows in VarSeq
An Exploration of Clinical Workflows in VarSeq
Golden Helix
Dr. Leroy Hood lectured to a group of Ohio State University College of Medicine students and faculty on May 13, 2010 in advance of an announcement of a partnership between the Ohio State University Medical Center and the Institute for Systems Biology. The partnership will be known as
Dr. Leroy Hood Lecuture on P4 Medicine
Dr. Leroy Hood Lecuture on P4 Medicine
The Ohio State University Wexner Medical Center
Pine Biotech held a workshop and discussion of the approaches that are being developed for the T-BioInfo platform. The approaches were presented by Julia Panov, a Ph.D. student from Haifa University and data scientist working at Pine Biotech. Her presentation covered some of the projects with preliminary results showing a promising method of integrating various omics data types and applying them to noisy datasets signal processing for target discovery and biomarkers. The workshop was held at the Flower Hall at Tulane University. This was the first presentation to over 40 people that gathered to discuss interesting applications of biomedical data analysis to healthcare and pharma. Dr. Yu-Ping Wang and Dr. Lars Gilbertson from the department of Biomedical Engineering also shared their perspective on this important topic. http://pine-biotech.com/workshop-roundtable-discussion-tulane-pine-biotech/
Tulane Workshop on Multi-omics integration
Tulane Workshop on Multi-omics integration
Elia Brodsky
Analysis and synthesis of a pulse survey conducted across >140 oncologists, pathologists, and lab directors regarding current adoption and trends associated with emerging oncology biomarkers and companion diagnostics (CDx), with an emphasis on next-generation sequencing (NGS)-based CDx.
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...
Andrew Aijian
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following: --Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals --Strategic client partnerships created by "Tech-Only" model --Dynamic, rapidly-growing and consolidating industry Industry-leading revenue & test volume growth --Strong productivity and operating leverage leading to accelerating cash flow and net income --Strong Management Team with large cap lab experience
Cancer Diagnostics Laboratory | NeoGenomics | April 2014 | Company Overview P...
Cancer Diagnostics Laboratory | NeoGenomics | April 2014 | Company Overview P...
NeoGenomics Laboratory | Cancer Diagnostics
Genomics, Bioinformatics, and Pathology
Genomics, Bioinformatics, and Pathology
Dan Gaston
AHIA 2011 Conference presentation by Prof Warwick Anderson, National health and Medical Research Centre
Genomics: The coming challenge to the health system
Genomics: The coming challenge to the health system
Private Healthcare Australia
http://www.fao.org/about/meetings/wgs-on-food-safety-management/en/ Web applications for rapid microbial taxonomy identification. Presentation from the Technical Meeting on the impact of Whole Genome Sequencing (WGS) on food safety management -23-25 May 2016, Rome, Italy.
Web applications for rapid microbial taxonomy identification
Web applications for rapid microbial taxonomy identification
ExternalEvents
VarSeq is a tertiary analysis platform that allows users to filter and annotate NGS sequencing data to identify clinically relevant variants. Following this workflow, VSClinical can then be used to automate both germline and somatic variant analysis in accordance with the ACMG and AMP guidelines by using a variety of functional prediction models and clinical and reviewer-based annotations. Once variant or biomarker interpretations are completed, they can be rendered in a customizable clinical report and stored in an internal assessment catalog as an internal variant database repository. Together, implementation of VSClinical will promote increased lab throughput as well as accuracy and compliance with the ACMG and AMP guidelines, which in turn can save time and money. To show the capabilities of our software, this webcast will provide a demonstration of how to use VarSeq and VSClinical for the evaluation of both germline and somatic variants in accordance with the ACMG and AMP Guidelines. In this webcast, we will cover: - Filter logics for germline and somatic variants and selecting them into the VSClinical interface - Capabilities of functional prediction and splice site algorithms for edge case variants - The functionality of changing the clinically relevant transcript on variant interpretation - Rendering a clinical report with germline and somatic variants with the inclusion of clinical trials
Next-Generation Sequencing Analysis in VSClinical
Next-Generation Sequencing Analysis in VSClinical
Golden Helix
Golden Helix has been in close communication with the publishers of the ACMG guidelines and the ClinGen group to receive expert advice on how to interpret CNVs called on NGS data. These guidelines provide a robust set of rules for interpreting intragenic deletions and duplications, which is summarized into an intricate decision tree that is broken down into 80 distinct criteria. This complexity is further compounded by many important caveats, exceptions, and considerations known to many in the CNV clinical workspace but are not mentioned in the published guidelines. Fortunately, Golden Helix has spent long hours reading the guidelines, watching the webinars, reading the supplementary material, and working with collaborators to develop a comprehensive workflow to guide you through your clinical interpretation of CNVs. Herein, we are excited to cover more details into this novel ACMG CNV guideline interpretation workflow and demonstrate how intuitive this feature can be for your clinical pipeline. Specifically, we will cover: The intricacies of the ACMG CNV Sample auto classifier Unique annotations and algorithms Adjustable metrics and parameters in the VSClinical ACMG interface Rendering clinical reports
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline Workflow
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline Workflow
Golden Helix
Darby Kammeraad, a Field Application Scientist at Golden Helix, gives some insight into the advantages of VarSeq's capability with annotations. The number of annotation topics to cover is seemingly limitless. In this webcast, he focuses on key elements that demonstrate the value of Golden Helix's curated annotations available in VarSeq and address some important considerations from our users. We also cover the types and effective utilization of annotations in VarSeq. Finally, he covers how users can create their own annotation sources from the Convert Wizard tool.
Annotation capabilities
Annotation capabilities
Golden Helix
What's hot
(19)
DNA & Personalized Medicine
DNA & Personalized Medicine
Gardner and Song_2015_Genetics in Medicine
Gardner and Song_2015_Genetics in Medicine
The BRCA Share(TM) Consortium - Christophe Beroud
The BRCA Share(TM) Consortium - Christophe Beroud
Establishing validity, reproducibility, and utility of highly scalable geneti...
Establishing validity, reproducibility, and utility of highly scalable geneti...
Meg Ehm: Fueling a Genetics-Driven Drug Discovery Organization
Meg Ehm: Fueling a Genetics-Driven Drug Discovery Organization
2016 ngs health_lecture
2016 ngs health_lecture
ClinVar: Aggregating Data to Improve Variant Interpretation - Melissa Landrum
ClinVar: Aggregating Data to Improve Variant Interpretation - Melissa Landrum
0301 ostrer
0301 ostrer
An Exploration of Clinical Workflows in VarSeq
An Exploration of Clinical Workflows in VarSeq
Dr. Leroy Hood Lecuture on P4 Medicine
Dr. Leroy Hood Lecuture on P4 Medicine
Tulane Workshop on Multi-omics integration
Tulane Workshop on Multi-omics integration
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...
Cancer Diagnostics Laboratory | NeoGenomics | April 2014 | Company Overview P...
Cancer Diagnostics Laboratory | NeoGenomics | April 2014 | Company Overview P...
Genomics, Bioinformatics, and Pathology
Genomics, Bioinformatics, and Pathology
Genomics: The coming challenge to the health system
Genomics: The coming challenge to the health system
Web applications for rapid microbial taxonomy identification
Web applications for rapid microbial taxonomy identification
Next-Generation Sequencing Analysis in VSClinical
Next-Generation Sequencing Analysis in VSClinical
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline Workflow
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline Workflow
Annotation capabilities
Annotation capabilities
Viewers also liked
Published in 2010, the MARS study outlines how consumers use the Web according to condition type and interests.
MARS Study Outlines Online Habits of Health Consumers
MARS Study Outlines Online Habits of Health Consumers
Path of the Blue Eye Project
Current status, cost, and applications of personal genome sequencing
DNA Testing: Living Longer Via Personal Genomics
DNA Testing: Living Longer Via Personal Genomics
Melanie Swan
헬스케어 빅데이터로 무엇을 할 수 있는가? 연구와 임상 적용 경험을 중심으로 (유전체, 전자의무기록, 건강보험청구자료, 영상, 센서/모바일)
헬스케어 빅데이터로 무엇을 할 수 있는가?
헬스케어 빅데이터로 무엇을 할 수 있는가?
Hyung Jin Choi
DNA Roulette was developed by Michigan State University professor Carrie Heeter and Stanford geneticist Barry Starr to help players understand what Direct to Consumer (DTC) testing does and does not tell you about your health. This presentation at Games for Health 2012 in Boston introduces the game.
DNA Roulette: Understanding genetics and genetic testing through gaming
DNA Roulette: Understanding genetics and genetic testing through gaming
carrie.heeter
An overview of the current regulatory environment. *This is not legal advice and is written by a non-attorney. This is general information from a student in law school (MSJ program).
Direct to Consumer Genetic Testing
Direct to Consumer Genetic Testing
Nathan J. Kerr
This is Part 1 of a presentation on Genetic Toxicology that was given by Dr. David Kirkland to scientific staff at Health Canada in Sept. 2010. Part 2 is availabile in ppt
Health Canada Genetic Tox Lecture Part 1
Health Canada Genetic Tox Lecture Part 1
cwoodland
대학원 강의
(서울의대 공유용) 빅데이터 분석 유전체 정보와 개인라이프로그 정보 활용-2015_11_24
(서울의대 공유용) 빅데이터 분석 유전체 정보와 개인라이프로그 정보 활용-2015_11_24
Hyung Jin Choi
Speaker: Patrice Sarrazin, PhD, Senior Scientific Evaluator, In Vitro Diagnostic Devices, Medical Devices Bureau, Therapeutic Product Directorate, Health Canada. Patrice discusses Health Canada's perspective on genetic testing as well as policy and regulation in Canada. Part of Dx2010, a workshop at MaRS focused on best practices and regulatory considerations for developing gene-based diagnostic and prognostic tests.
Regulatory oversight of genetic testing in Canada: Health Canada perspective
Regulatory oversight of genetic testing in Canada: Health Canada perspective
MaRS Discovery District
의료 빅데이터와 인공지능의 현재와 미래
의료 빅데이터와 인공지능의 현재와 미래
의료 빅데이터와 인공지능의 현재와 미래
Hyung Jin Choi
Richard Sharp, Ph.D., Director of Bioethics Research at the Cleveland Clinic presents on direct-to-consumer genomics and the future of health care. Dr. Sharp received his training in philosophy and medical ethics at Michigan State University. Prior to joining the Cleveland Clinic in 2007, Dr. Sharp taught bioethics at Baylor College of Medicine and the National Institute of Environmental Health Sciences, one of the National Institutes of Health (NIH), where he directed the Program in Environmental Health Policy and Ethics. His research examines the promotion of informed patient decision-making in clinical research, particularly research that involves genetic analyses.
Direct To Consumer Genomics and the Future of Healthcare
Direct To Consumer Genomics and the Future of Healthcare
Ryan Squire
Medical utopias are often about good health, absence of suffering, and even delaying of the aging process. The last two decades have seen a tremendous increase in emerging medical technologies to achieve these utopias. The completion of the sequencing of the human genome sets the stage for the next step of genetic and molecular advances. The increase in computing power, storage capacity, connectivity, and the Internet has opened avenues of new diagnostic and therapeutic modalities. The perfecting of sustaining cell growth in vitro and cell nucleus transfer has opened the way to cloning, stem cell harvesting, and a new field of regenerative medicine. However, these emerging technologies bring with them a large number of bioethical concerns that need to be addressed. These concerns involving tissue engineering, bioelectronics, new genetics, cloning, gene therapy, germ-line genome modifications are only the tip of the iceberg. In this paper I will reflect on three areas of concern. Firstly, the emergence of the digital patient will be considered. This digital patient will be deeply formed and informed by health information technology (IT), the social media, and issues involving privacy, confidentiality and data security. Secondly, the direct to customers (DTC) genetic screening tests will be discussed. The ethical issue of buccal swabs taken at home and be tested for genetic diseases and future prediction of other illnesses which is marketed directly to the consumers will be examined. Finally, the development of new pharmaco-therapeutics will be explored. There have been changes in the way new drugs are tested and these changes do raise some ethical concerns. The examination of these ethical issues will be done in the framework of respect for autonomy, beneficence, non-maleficence, and justice.
Medical Utopias: The Promise of Emerging Technologies
Medical Utopias: The Promise of Emerging Technologies
Alex Tang
A look at future directions for biology. Personalized genomics is a key step in moving towards individualized medicine and preventative interventions. The traditional trial and error approach of molecular biology is being replaced by the direct design of synthetic biology. Synthetically developed energy solutions could have a substantial impact on natural resource demand.
Biology Futures
Biology Futures
Melanie Swan
You're driving down the highway, when suddenly you spot a police officer or a state trooper in your rearview mirror. You're driving the speed limit; your tags are up-to-date, yet you suddenly feel guilty – like you've done something wrong. This is how the FDA makes us feel when it comes to running direct-to-consumer (DTC) advertising for medical devices and pharmaceuticals. More often than not, you aren't doing anything wrong. But your anxiety levels run high as soon as you step on the gas.
Why DTC Advertising Shouldn't Make Us Feel Guilty
Why DTC Advertising Shouldn't Make Us Feel Guilty
Grey Matter Marketing
CMI/Compas Study on Doctors’ Views of Direct-to-Consumer Drug Advertising, April 2013, In Preparation for the FDA Survey of Clinicians on Direct-to-Consumer Drug Advertising
Doctors’ Views of Direct-to-Consumer Drug Advertising
Doctors’ Views of Direct-to-Consumer Drug Advertising
CMI_Compas
Genetic testing
Genetic testing
Shenellie Harry
These slides use concepts from my (Jeff Funk) course entitled Biz Models for Hi-Tech Products to analyze the business model for 23andMe’s personal genomics service. 23andMe provides personal health care analysis and ancestry information to individuals that are based on a partial analysis of an individual’s DNA data. Driven by the falling cost of DNA sequencing, 23 and Me provides this information for $99 and a small amount of saliva. While this business model may succeed particularly if the FDA eventually approves the health care portion of the service, we recommend that 23andMe develop a new business model. It should offer the service for free to individuals, particularly those who frequent gyms and nutrition stores and sell information about potential athletes to sports teams.
Personal Genomics: Business Model for 23andMe
Personal Genomics: Business Model for 23andMe
Jeffrey Funk Business Models
Genomics
Genomics
Genomics
Amna Jalil
for m.sc nsg student
Genetic testing
Genetic testing
Shaells Joshi
최윤섭 디지털 헬스케어 연구소에서 주최하는 2016년 1분기 글로벌 디지털 헬스케어 산업 동향을 살펴보는 온라인 세미나입니다. 지난 1-3월 동안 디지털 헬스케어 분야에서 있었던 국내외 주요 이슈들을 간략하게 살펴봅니다.
디지털 헬스케어 글로벌 동향: 2016년 1분기 (Global Digital Healthcare Trends: 2016 1Q)
디지털 헬스케어 글로벌 동향: 2016년 1분기 (Global Digital Healthcare Trends: 2016 1Q)
Yoon Sup Choi
Digital marketing in pharmaceuticals Long term relationships Empowered stakeholders
It's not you , it's me
It's not you , it's me
goombie
Viewers also liked
(20)
MARS Study Outlines Online Habits of Health Consumers
MARS Study Outlines Online Habits of Health Consumers
DNA Testing: Living Longer Via Personal Genomics
DNA Testing: Living Longer Via Personal Genomics
헬스케어 빅데이터로 무엇을 할 수 있는가?
헬스케어 빅데이터로 무엇을 할 수 있는가?
DNA Roulette: Understanding genetics and genetic testing through gaming
DNA Roulette: Understanding genetics and genetic testing through gaming
Direct to Consumer Genetic Testing
Direct to Consumer Genetic Testing
Health Canada Genetic Tox Lecture Part 1
Health Canada Genetic Tox Lecture Part 1
(서울의대 공유용) 빅데이터 분석 유전체 정보와 개인라이프로그 정보 활용-2015_11_24
(서울의대 공유용) 빅데이터 분석 유전체 정보와 개인라이프로그 정보 활용-2015_11_24
Regulatory oversight of genetic testing in Canada: Health Canada perspective
Regulatory oversight of genetic testing in Canada: Health Canada perspective
의료 빅데이터와 인공지능의 현재와 미래
의료 빅데이터와 인공지능의 현재와 미래
Direct To Consumer Genomics and the Future of Healthcare
Direct To Consumer Genomics and the Future of Healthcare
Medical Utopias: The Promise of Emerging Technologies
Medical Utopias: The Promise of Emerging Technologies
Biology Futures
Biology Futures
Why DTC Advertising Shouldn't Make Us Feel Guilty
Why DTC Advertising Shouldn't Make Us Feel Guilty
Doctors’ Views of Direct-to-Consumer Drug Advertising
Doctors’ Views of Direct-to-Consumer Drug Advertising
Genetic testing
Genetic testing
Personal Genomics: Business Model for 23andMe
Personal Genomics: Business Model for 23andMe
Genomics
Genomics
Genetic testing
Genetic testing
디지털 헬스케어 글로벌 동향: 2016년 1분기 (Global Digital Healthcare Trends: 2016 1Q)
디지털 헬스케어 글로벌 동향: 2016년 1분기 (Global Digital Healthcare Trends: 2016 1Q)
It's not you , it's me
It's not you , it's me
Similar to 2010StanfordE25 Michele dragoescu e25 project
Slides for meeting to be held March 14th in Philadelphia - indications discovery and drug repurposing
Indications discovery and drug repurposing
Indications discovery and drug repurposing
Sean Ekins
Cancer genome repository_berkeley
Cancer genome repository_berkeley
Shyam Sarkar
As medical understanding of the genotype/phenotype correlation of a disease becomes clearer, genetic testing can be expected to become a mainstay in the clinical setting. While the application of genetic testing to the clinical setting is very much in line with the larger medical goals of preventative and personalized medicine, there are many unanswered questions with regard to genetic testing. Speakers: Dr. Mansoor Mohammed, Genomics Portraits Inc., Dr. Brian Underdown, Managing Director, MDS Capital, Dr. June Carroll, Sydney G. Frankfort Chair in Family Medicine Mt.Sinai Hospital, Dr. Peter N. Ray, Head, Molecular Genetics Department of Paediatric Laboratory Medicine. HSC Professor, Molecular and Medical Genetics, University of Toronto
Personalized Medicine: Genetic Diagnostics Technologies
Personalized Medicine: Genetic Diagnostics Technologies
MaRS Discovery District
Reg Sci Lecture Dec 2016
Reg Sci Lecture Dec 2016
Rick Silva
Quantitative Medicine Feb 2009
Quantitative Medicine Feb 2009
Ian Foster
With the exponential growth of genomic data sets, healthcare practitioners now have the opportunity to improve human outcomes at an unprecedented pace. These outcomes are difficult to realize in the existing ecosystem of genomic tools, where biostatisticians regularly chain together command-line interfaces based on a single-node setup on premise. The Databricks Unified Analytics Platform for Genomics empowers users to perform end-to-end analysis on our massively scalable platform in the cloud: in only minutes, a data scientist can visualize an individual’s disease risk based on their raw genomic data. Built on Apache Spark, we provide click-button implementations of accepted best practice workflows, as well as low-level Spark SQL optimizations for common genomics operations.
From Genomics to Medicine: Advancing Healthcare at Scale
From Genomics to Medicine: Advancing Healthcare at Scale
Databricks
JALANov2000
JALANov2000
Ellie Nawara
This presentation introduces and discussesthe concept of ‘morphologomics’ that is omics approaches critically reimagined and reappraised from the viewpoint of classic morphology. It was delivered by Dr. Anthony Gill at the Pathology Horizons 2017 conference in Cairns, Australia. introduce and discuss the concept of ‘morphologomics’ that is omics approaches critically reimagined and reappraised from the viewpoint of classic morphology.
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...
Cirdan
This presentation goes in-depth in the growing field of personal genome sequencing. The advances in high-throughput DNA sequencing has made the process of mapping structural deviations in an individual's genetic totality more economical. The advantages in health care makes this technology more like to be fully integrated in medicine within the next ten years.
Clinical Assessment In Incorporating a Personal Genome
Clinical Assessment In Incorporating a Personal Genome
Diego Herrera
This year's 3rd Annual TCGC: The Clinical Genome Conference, held June 10-12, 2014 in San Francisco, is a three-day event that weaves together the science of sequencing and the business of implementing genomics in the clinic. It uniquely illustrates the mutual influence of those areas and the need to therefore consider the needs, challenges and opportunities of both - from next-generation sequencing and variant interpretation to insurance reimbursement and electronic health records - throughout the entire research process.Learn more at http://www.clinicalgenomeconference.com
The Clinical Genome Conference 2014
The Clinical Genome Conference 2014
Nicole Proulx
Collaborative innovation in biomedicine talk, April 5 2011
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
Sean Ekins
Data Mining and Big Data Analytics in Pharma
Data Mining and Big Data Analytics in Pharma
Ankur Khanna
Talk from 2010 ACS in boston
acs talk open source drug discovery
acs talk open source drug discovery
Sean Ekins
Bio-informatics
Homework
Homework
harshi2911
A presentation by Labros Digonis
InSyBio at Open Coffee Athens CI
InSyBio at Open Coffee Athens CI
Open Coffee Greece
Emerging collaboration models for academic medical centers _ our place in the...
Emerging collaboration models for academic medical centers _ our place in the...
Rick Silva
Fda phacilitate2010final
Fda phacilitate2010final
isoasp
Context Drug agencies encourage more and more the use of information technologies to improve models to predict the efficacy and safety of submitted drug candidates. These models require various tools as well as reliable in silico, in vitro and in vivo data. The selection of qualitative experimental data is critical to the efficiency of the predictive models. Aureus' Solutions Aureus Sciences has developed a recognized expertise on building knowledge bases with industrial partners in a collaborative approach, for the organization and storage of experimental data to help the pharmaceutical industry improve predictive approaches to drug discovery and development projects.
Predicting Drug Candidates Safety : the Role and Usage of Knowledge Bases
Predicting Drug Candidates Safety : the Role and Usage of Knowledge Bases
Aureus Sciences
Diabetes Systems Biology And Genetics V6
Diabetes Systems Biology And Genetics V6
cphensley
Dreyfuss.berkeley.2010
Dreyfuss.berkeley.2010
Open Science Summit
Similar to 2010StanfordE25 Michele dragoescu e25 project
(20)
Indications discovery and drug repurposing
Indications discovery and drug repurposing
Cancer genome repository_berkeley
Cancer genome repository_berkeley
Personalized Medicine: Genetic Diagnostics Technologies
Personalized Medicine: Genetic Diagnostics Technologies
Reg Sci Lecture Dec 2016
Reg Sci Lecture Dec 2016
Quantitative Medicine Feb 2009
Quantitative Medicine Feb 2009
From Genomics to Medicine: Advancing Healthcare at Scale
From Genomics to Medicine: Advancing Healthcare at Scale
JALANov2000
JALANov2000
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...
Clinical Assessment In Incorporating a Personal Genome
Clinical Assessment In Incorporating a Personal Genome
The Clinical Genome Conference 2014
The Clinical Genome Conference 2014
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
Data Mining and Big Data Analytics in Pharma
Data Mining and Big Data Analytics in Pharma
acs talk open source drug discovery
acs talk open source drug discovery
Homework
Homework
InSyBio at Open Coffee Athens CI
InSyBio at Open Coffee Athens CI
Emerging collaboration models for academic medical centers _ our place in the...
Emerging collaboration models for academic medical centers _ our place in the...
Fda phacilitate2010final
Fda phacilitate2010final
Predicting Drug Candidates Safety : the Role and Usage of Knowledge Bases
Predicting Drug Candidates Safety : the Role and Usage of Knowledge Bases
Diabetes Systems Biology And Genetics V6
Diabetes Systems Biology And Genetics V6
Dreyfuss.berkeley.2010
Dreyfuss.berkeley.2010
Recently uploaded
Sidekick Solutions uses Bonterra Impact Management (fka Social Solutions Apricot) and automation solutions to integrate data for business workflows. We believe integration and automation are essential to user experience and the promise of efficient work through technology. Automation is the critical ingredient to realizing that full vision. We develop integration products and services for Bonterra Case Management software to support the deployment of automations for a variety of use cases. This video focuses on the deployment of external web forms using Jotform for Bonterra Impact Management. This solution can be customized to your organization’s needs and deployed to support the common use cases below: - Intake and consent - Assessments - Surveys - Applications - Program registration Interested in deploying web form automations for Bonterra Impact Management? Contact us at sales@sidekicksolutionsllc.com to discuss next steps.
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Jeffrey Haguewood
Uncertainty, Acting under uncertainty, Basic probability notation, Bayes’ Rule,
Artificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : Uncertainty
Khushali Kathiriya
Terragrunt, Terraspace, Terramate, terra... whatever. What is wrong with Terraform so people keep on creating wrappers and solutions around it? How OpenTofu will affect this dynamic? In this presentation, we will look into the fundamental driving forces behind a zoo of wrappers. Moreover, we are going to put together a wrapper ourselves so you can make an educated decision if you need one.
AWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of Terraform
Andrey Devyatkin
Following the popularity of "Cloud Revolution: Exploring the New Wave of Serverless Spatial Data," we're thrilled to announce this much-anticipated encore webinar. In this sequel, we'll dive deeper into the Cloud-Native realm by uncovering practical applications and FME support for these new formats, including COGs, COPC, FlatGeoBuf, GeoParquet, STAC, and ZARR. Building on the foundation laid by industry leaders Michelle Roby of Radiant Earth and Chris Holmes of Planet in the first webinar, this second part offers an in-depth look at the real-world application and behind-the-scenes dynamics of these cutting-edge formats. We will spotlight specific use-cases and workflows, showcasing their efficiency and relevance in practical scenarios. Discover the vast possibilities each format holds, highlighted through detailed discussions and demonstrations. Our expert speakers will dissect the key aspects and provide critical takeaways for effective use, ensuring attendees leave with a thorough understanding of how to apply these formats in their own projects. Elevate your understanding of how FME supports these cutting-edge technologies, enhancing your ability to manage, share, and analyze spatial data. Whether you're building on knowledge from our initial session or are new to the serverless spatial data landscape, this webinar is your gateway to mastering cloud-native formats in your workflows.
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Safe Software
Webinar Recording: https://www.panagenda.com/webinars/why-teams-call-analytics-is-critical-to-your-entire-business Nothing is as frustrating and noticeable as being in an important call and being unable to see or hear the other person. Not surprising then, that issues with Teams calls are among the most common problems users call their helpdesk for. Having in depth insight into everything relevant going on at the user’s device, local network, ISP and Microsoft itself during the call is crucial for good Microsoft Teams Call quality support. To ensure a quick and adequate solution and to ensure your users get the most out of their Microsoft 365. But did you know that ‘bad calls’ are also an excellent indicator of other problems arising? Precisely because it is so noticeable!? Like the canary in the mine, bad calls can be early indicators of problems. Problems that might otherwise not have been noticed for a while but can have a big impact on productivity and satisfaction. Join this session by Christoph Adler to learn how true Microsoft Teams call quality analytics helped other organizations troubleshoot bad calls and identify and fix problems that impacted Teams calls or the use of Microsoft365 in general. See what it can do to keep your users happy and productive! In this session we will cover - Why CQD data alone is not enough to troubleshoot call problems - The importance of attributing call problems to the right call participant - What call quality analytics can do to help you quickly find, fix-, and prevent problems - Why having retrospective detailed insights matters - Real life examples of how others have used Microsoft Teams call quality monitoring to problem shoot problems with their ISP, network, device health and more.
Why Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire business
panagenda
FWD Group - Insurer Innovation Award 2024
FWD Group - Insurer Innovation Award 2024
FWD Group - Insurer Innovation Award 2024
The Digital Insurer
ICT role in education and it's challenges. In which we learn about ICT, it's impact, benefits and challenges.
ICT role in 21st century education and its challenges
ICT role in 21st century education and its challenges
rafiqahmad00786416
Explore how multimodal embeddings work with Milvus. We will see how you can explore a popular multimodal model - CLIP - on a popular dataset - CIFAR 10. You use CLIP to create the embeddings of the input data, Milvus to store the embeddings of the multimodal data (sometimes termed “multimodal embeddings”), and we will then explore the embeddings.
Exploring Multimodal Embeddings with Milvus
Exploring Multimodal Embeddings with Milvus
Zilliz
In this talk, we are going to cover the use-case of food image generation at Delivery Hero, its impact and the challenges. In particular, we will present our image scoring solution for filtering out inappropriate images and elaborate on the models we are using.
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
Zilliz
DBX 1Q24 Investor Presentation
DBX First Quarter 2024 Investor Presentation
DBX First Quarter 2024 Investor Presentation
Dropbox
Retrieval augmented generation (RAG) is the most popular style of large language model application to emerge from 2023. The most basic style of RAG works by vectorizing your data and injecting it into a vector database like Milvus for retrieval to augment the text output generated by an LLM. This is just the beginning. One of the ways that we can extend RAG, and extend AI, is through multilingual use cases. Typical RAG is done in English using embedding models that are trained in English. In this talk, we’ll explore how RAG could work in languages other than English. We’ll explore French, Chinese, and Polish.
Introduction to Multilingual Retrieval Augmented Generation (RAG)
Introduction to Multilingual Retrieval Augmented Generation (RAG)
Zilliz
Dubai, often portrayed as a shimmering oasis in the desert, faces its own set of challenges, including the occasional threat of flooding. Despite its reputation for opulence and modernity, the emirate is not immune to the forces of nature. In recent years, Dubai has experienced sporadic but significant floods, testing the resilience of its infrastructure and communities. Among the critical lifelines in this bustling metropolis is the Dubai International Airport, a bustling hub that connects the city to the world. This article explores the intersection of Dubai flood events and the resilience demonstrated by the Dubai International Airport in the face of such challenges.
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Orbitshub
How to get Oracle DBA Job as fresher.
Strategies for Landing an Oracle DBA Job as a Fresher
Strategies for Landing an Oracle DBA Job as a Fresher
Remote DBA Services
Tracing the root cause of a performance issue requires a lot of patience, experience, and focus. It’s so hard that we sometimes attempt to guess by trying out tentative fixes, but that usually results in frustration, messy code, and a considerable waste of time and money. This talk explains how to correctly zoom in on a performance bottleneck using three levels of profiling: distributed tracing, metrics, and method profiling. After we learn to read the JVM profiler output as a flame graph, we explore a series of bottlenecks typical for backend systems, like connection/thread pool starvation, invisible aspects, blocking code, hot CPU methods, lock contention, and Virtual Thread pinning, and we learn to trace them even if they occur in library code you are not familiar with. Attend this talk and prepare for the performance issues that will eventually hit any successful system. About authorWith two decades of experience, Victor is a Java Champion working as a trainer for top companies in Europe. Five thousands developers in 120 companies attended his workshops, so he gets to debate every week the challenges that various projects struggle with. In return, Victor summarizes key points from these workshops in conference talks and online meetups for the European Software Crafters, the world’s largest developer community around architecture, refactoring, and testing. Discover how Victor can help you on victorrentea.ro : company training catalog, consultancy and YouTube playlists.
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Victor Rentea
Six common myths about ontology engineering, knowledge graphs, and knowledge representation.
Six Myths about Ontologies: The Basics of Formal Ontology
Six Myths about Ontologies: The Basics of Formal Ontology
johnbeverley2021
Accelerating FinTech Innovation: Unleashing API Economy and GenAI Vasa Krishnan, Chief Technology Officer - FinResults Apidays New York 2024: The API Economy in the AI Era (April 30 & May 1, 2024) ------ Check out our conferences at https://www.apidays.global/ Do you want to sponsor or talk at one of our conferences? https://apidays.typeform.com/to/ILJeAaV8 Learn more on APIscene, the global media made by the community for the community: https://www.apiscene.io Explore the API ecosystem with the API Landscape: https://apilandscape.apiscene.io/
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
apidays
Corporate and higher education. Two industries that, in the past, have had a clear divide with very little crossover. The difference in goals, learning styles and objectives paved the way for differing learning technologies platforms to evolve. Now, those stark lines are blurring as both sides are discovering they have content that’s relevant to the other. Join Tammy Rutherford as she walks through the pros and cons of corporate and higher ed collaborating. And the challenges of these different technology platforms working together for a brighter future.
Corporate and higher education May webinar.pptx
Corporate and higher education May webinar.pptx
Rustici Software
This reviewer is for the second quarter of Empowerment Technology / ICT in Grade 11
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
MadyBayot
Three things you will take away from the session: • How to run an effective tenant-to-tenant migration • Best practices for before, during, and after migration • Tips for using migration as a springboard to prepare for Copilot in Microsoft 365 Main ideas: Migration Overview: The presentation covers the current reality of cross-tenant migrations, the triggers, phases, best practices, and benefits of a successful tenant migration Considerations: When considering a migration, it is important to consider the migration scope, performance, customization, flexibility, user-friendly interface, automation, monitoring, support, training, scalability, data integrity, data security, cost, and licensing structure Next Wave: The next wave of change includes the launch of Copilot, which requires businesses to be prepared for upcoming changes related to Copilot and the cloud, and to consolidate data and tighten governance ShareGate: ShareGate can help with pre-migration analysis, configurable migration tool, and automated, end-user driven collaborative governance
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
sammart93
MINDCTI Revenue Release Quarter 1 2024
MINDCTI Revenue Release Quarter One 2024
MINDCTI Revenue Release Quarter One 2024
MIND CTI
Recently uploaded
(20)
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Artificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : Uncertainty
AWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of Terraform
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Why Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire business
FWD Group - Insurer Innovation Award 2024
FWD Group - Insurer Innovation Award 2024
ICT role in 21st century education and its challenges
ICT role in 21st century education and its challenges
Exploring Multimodal Embeddings with Milvus
Exploring Multimodal Embeddings with Milvus
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
DBX First Quarter 2024 Investor Presentation
DBX First Quarter 2024 Investor Presentation
Introduction to Multilingual Retrieval Augmented Generation (RAG)
Introduction to Multilingual Retrieval Augmented Generation (RAG)
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Strategies for Landing an Oracle DBA Job as a Fresher
Strategies for Landing an Oracle DBA Job as a Fresher
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Six Myths about Ontologies: The Basics of Formal Ontology
Six Myths about Ontologies: The Basics of Formal Ontology
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Corporate and higher education May webinar.pptx
Corporate and higher education May webinar.pptx
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
MINDCTI Revenue Release Quarter One 2024
MINDCTI Revenue Release Quarter One 2024
2010StanfordE25 Michele dragoescu e25 project
1.
By Michele Dragoescu
E25, 2010
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
Pharmacogenomic Database
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
Editor's Notes
http://www.chicagotribune.com/business/ct-biz-0512-genetic-tests-20100511,0,7466502.story for more
Download now